Abstract: The present invention relates to a polymer/filler/metal composite fiber, including a polymer fiber comprising a metal short fiber and a filler; the metal short fiber is distributed as a dispersed phase within the polymer fiber and distributed in parallel to the axis of the polymer fiber; the filler is dispersed within the polymer fiber and distributed between the metal short fibers; the filler does not melt at the processing temperature of the polymer; said metal is a low melting point metal and selected from at least one of single component metals and metal alloys, and has a melting point which ranges from 20 to 480° C., and, at the same time, which is lower than the processing temperature of the polymer; the metal short fiber and the polymer fiber have a volume ratio of from 0.01:100 to 20:100; the filler and the polymer have a weight ratio of from 0.1:100 to 30:100.

Abstract: Antimicrobial cationic polymers having one or two cationic polycarbonate chains were prepared by organocatalyzed ring opening polymerization. One antimicrobial cationic polymer has a polymer chain consisting essentially of cationic carbonate repeat units linked to one or two end groups. The end groups can comprise a covalently bound form of biologically active compound such as cholesterol. Other antimicrobial cationic polymers have a random copolycarbonate chain comprising a minor mole fraction of hydrophobic repeat units bearing a covalently bound form of a vitamin E and/or vitamin D2. The cationic polymers exhibit high activity and selectivity against Gram-negative and Gram-positive microbes and fungi.

Abstract: Genetically modified non-human animals are provided that may be used to model human hematopoietic cell development, function, or disease. The genetically modified non-human animals comprise a nucleic acid encoding human IL-6 operably linked to an IL-6 promoter. In some instances, the genetically modified non-human animal expressing human IL-6 also expresses at least one of human M-CSF, human IL-3, human GM-CSF, human SIRPa or human TPO. In some instances, the genetically modified non-human animal is immunodeficient. In some such instances, the genetically modified non-human animal is engrafted with healthy or diseased human hematopoietic cells. Also provided are methods for using the subject genetically modified non-human animals in modeling human hematopoietic cell development, function, and/or disease, as well as reagents and kits thereof that find use in making the subject genetically modified non-human animals and/or practicing the subject methods.

Abstract: A measurement system and a measurement method using the same are provided. Firstly, a measurement system is provided. The measurement system comprises a film, a sensor and a movement information calculator, wherein the film has a patterned structure layer, and the sensor is electrically isolated from and selectively in contact with the film. Then, the sensor directly contacts the patterned structure layer and generates a sensing signal during relative movement process between the sensor and the film. Then, the movement information calculator obtains at least one of a relative movement amount and a relative movement speed during the relative movement process according to the sensing signal.

Abstract: A surgical image pickup system utilizes an adjustable lens set and a complex lens set to change the direction of the incident light emitted from the light source and the position of the surgical site on which the incident light projects. The eyepiece and the sensor have the same field of view and the same optical axis such that first image generated by the sensor and a second image generated by the eyepiece are the same. The sensor transmits the first image to the external display for display by wireless communication. By means of the foregoing configuration, the second image which doctor utilizes the eyepiece to see and the first image which the external display displays are the same, thereby facilitating the operation of surgery.

Abstract: The present disclosure illustrates a map creation system and a method for a movable robot. The map creation system includes a movable robot and a display device. The movable robot includes a robot body; a driving unit driving the robot body to move in a space; an image capturing unit capturing a image in the space; a sampling unit sampling in the space to obtain a sample; a control unit controlling the operation of the driving unit, the image capturing unit and the sampling unit; and a power supply unit supplying an electrical power to each unit. The display device displays the received image and marks a location in the space where the sample is obtained on the image, and synchronously displays a movement trace of the movable robot in the space according to the driving instructions of the driving unit.

Abstract: An aerosol liposome of a marine extract and a method of producing the same are introduced. The marine extract is extracted from cell membranes of marine processing streams, including phosphatidylserine (PS), phosphatidylcholine (PC), phosphatidylethanolamine (PE), phosphatidylinositol (PI), and lysophosphatidylcholine (LysoPC), further including at least phosphatidylserine (PS). The aerosol liposome is of a particle diameter of less than 2,000 nm. The surface of the aerosol liposome carries phosphatidylserine (PS) molecules. The aerosol liposome of a marine extract, thus provided, is simple and stable and can be absorbed through the mouth, nose, upper respiratory tract, and epidermis and engulfed by macrophages therein to quickly alleviate or regulate systematic inflammatory responses and prevent inflammation-related diseases.

Abstract: Embodiments of the invention are directed to a method for production of a nuclear fuel pellet by spark plasma sintering (SPS), wherein a fuel pellet with more than 80% TD or more than 90% TD is formed. The SPS can be performed with the imposition of a controlled uniaxial pressure applied at the maximum temperature of the processing to achieve a very high density, in excess of 95% TD, at temperatures of 850 to 1600° C. The formation of a fuel pellet can be carried out in one hour or less. In an embodiment of the invention, a nuclear fuel pellet comprises UO2 and a highly thermally conductive material, such as SiC or diamond.

Abstract: An acoustic wave filter device is disclosed. The device includes an acoustic wave filter element, and a first resonator and a second resonator coupled to the acoustic wave filter element. The acoustic wave filter element includes interdigited input electrodes and output electrodes located on a top surface of a piezoelectric layer and an counter-electrode on the bottom surface of the piezoelectric layer. Each of the first and the second resonators includes a resonator electrode on the top surface of the piezoelectric layer and a resonator counter-electrode on the bottom surface of the piezoelectric layer. The first resonator has a first notch in resonator impedance at a first frequency. The second resonator includes a first mass loading layer on the second resonator electrode such that the second resonator has a second notch in resonator impedance at a second frequency that is different from the first frequency.

Abstract: A quantum computer architecture employs logical qubits that are constructed from a concatenation of doubly periodic Josephson junction circuits. The series concatenation of the doubly periodic Josephson junction circuits provides exponential robustness against local noise. It is possible to perform discrete Clifford group rotations and entangling operations on the logical qubits without leaving the protected state.

Abstract: Disclosed herein are a method and apparatus for virtual desktop service. The apparatus includes a connection manager configured to perform an assignment task of assigning a virtual machine to a user terminal using virtual desktop service, a resource pool configured to allocate software resources to a virtual desktop, wherein the software resources include an OS, applications, and user profiles, and a virtual machine infrastructure configured to support hardware resources including a CPU and a memory, wherein the connection manager is configured to perform a coordination task of coordinating a delivery protocol used between the user terminal and servers that provide the virtual desktop service, wherein the resource pool has a management function, wherein the management function is based on usage pattern information about a user's average usage of resources, and wherein the management function uses a physical distance on network from the user terminal to a server.

Abstract: A method for preventing, improving, or treating fatty liver includes administering an effective amount of an azelaic acid or a pharmaceutically acceptable salt thereof to a subject. Azelaic acid which is a compound primarily contained in a natural product, has no or fewer side effects and reduces accumulation of triglycerides in liver tissue, and thus may prevent, improve, or treat a non-alcoholic fatty liver. In addition, due to an anti-inflammatory effect, azelaic acid may be used in the treatment of steatohepatitis. Therefore, the azelaic acid according to the present disclosure is expected to be effectively used in a food composition, a pharmaceutical composition and a health functional food composition to treat fatty liver or steatohepatitis.

Abstract: A solid-state lubricant composition is disclosed. The solid-lubricant contains graphene, an oxide of a metal, and one or more polymeric binders. A method of making a solid-state lubricant coating on various substrates is disclosed. The method includes the steps of making a homogeneous slurry comprising powder of an oxide of a metal, graphene, and a polymeric binder with organic volatile solvent; coating a substrate with the homogeneous slurry with desired thicknesses; and drying the slurry on the substrate naturally or applying additional heat, resulting in a solid lubricant coating on the substrate. Substrates with coated solid composite lubricant show wear reduction and lower coefficient of friction compared with uncoated substrates.

Abstract: A polymer is provided, which is formed by reacting a diol having hydrogenated bisphenol group with a bis-epoxy compound. The diol having hydrogenated bisphenol group may have a chemical structure of wherein each of R1 is independently H or methyl, and m and n are independently integers of 1 to 4. The bis-epoxy compound can be or a combination thereof, wherein each of R2 is independently H or methyl, and each of R3 is independently H or methyl.

Abstract: Provided is an apparatus and method for dynamically communicating information of an area of interest by way of road marker devices, such as road cones, pucks, barricade, or the like. The apparatus may communication information for areas of interest including road work zones, traffic accidents, disabled vehicles, or other road hazards. The road marker devices include processing circuitry configured to determine a peripheral shape as a boundary indicated by the road marker devices as the information of the area of interest, and communicate the information of the peripheral shape from a marker device to vehicles approaching the area of interest. The road markers may communicate information of the area of interest to autonomous vehicles, or vehicles having certain sensors.

Abstract: The present disclosure discloses a novel omniphobic, paper-based, smart bandage (OPSB) devices, and the methods to make and use the omniphobic, paper-based, smart bandage devices. The OPSB device of the present disclosure provides a simple, low-cost, and non-invasive strategy to monitor open wound status wirelessly. This disclosure also provides the demonstration of in-vivo early detection and monitoring of pressure ulcers using wireless smart bandages.

Abstract: The present disclosure provides methods of treating a patient comprising administering a p38 inhibitor for the treatment of FSHD. In some embodiments, the present methods comprise using one or more p38 inhibitors as a therapeutic agent for the treatment of FSHD patients including patients who are being treated with one or more palliative treatments such as therapy and/or agents which lead to increased muscle mass.

Abstract: Methods are provided for the treatment of relapsed and/or refractory solid tumors (including neuroendocrine carcinomas (NEC)) and non-Hodgkin's lymphomas (NHLs) and the like, using substituted heterocyclic derivative compounds and pharmaceutical compositions comprising compounds useful for the inhibition of lysine specific demethylase-1 (LSD-1).

Abstract: Disclosed herein is a method of creating an image stitching workflow including acquiring 360-degree virtual reality (VR) image parameters necessary to makes a request for image stitching and create the image stitching workflow, acquiring a list of functions applicable to the image stitching workflow, creating the image stitching workflow based on functions selected from the list of functions, determining the number of media processing entities necessary to perform tasks configuring the image stitching workflow and generating a plurality of media processing entities according to the determined number of media processing entities, and allocating the tasks configuring the image stitching workflow to the plurality of media processing entities.

Abstract: This invention is directed to pyrrole, pyrazole, imidazole, triazole, and morpholine based selective androgen receptor degrader (SARD) compounds including heterocyclic anilide rings and their synthetic precursors, R-isomers, and non-hydroxylated and/or non-chiral propanamides, and pharmaceutical compositions and uses thereof in treating prostate cancer, advanced prostate cancer, castration resistant prostate cancer, triple negative breast cancer, other cancers expressing the androgen receptor, androgenic alopecia or other hyperandrogenic dermal diseases, Kennedy's disease, amyotrophic lateral sclerosis (ALS), abdominal aortic aneurysm (AAA), and uterine fibroids, and to methods for reducing the levels of androgen receptor-full length (AR-FL) including pathogenic or resistance mutations, AR-splice variants (AR-SV), and pathogenic polyglutamine (polyQ) polymorphisms of AR in a subject.